From October 14 to 15, 2017, the third histone deacetylase inhibitor (HDACi) summit was solemnly held in the beautiful ancient city of Nanjing. HDACi summit is an annual large-scale blood tumor academic gathering held by CHIPSCREEN BIOSCIENCES  since its listing in Chidamide. The summit invited top experts in hematology in China to discuss the clinical application and research progress of HDACi. Professor Jiang Wenqi from the cancer prevention and treatment center of Yat-sen University, Professor Shen Zhixiang from the Ruijin hospital affiliated to Shanghai Jiao Tong University, Professor Qiu Lugui from the blood disease hospital of the Chinese Academy of Medical Sciences, Professor Ma Jun from the Harbin blood disease tumor research institute, Professor Feng Jifeng from Jiangsu tumor hospital, Professor Zhou Daobin from Peking union hospital, Professor Liu Ting from West China hospital and Professor Li Jianyong from the first affiliated hospital of Nanjing medical University attended the conference and were invited to serve as the president of the conference with different topics. The conference attracted more than 200 experts of blood tumor from all over the country.

Dr. Lu Xianping, the president and chief scientific officer of CHIPSCREEN BIOSCIENCES, first made a wonderful report for the conference, "HDACi leads new ideas of treatment from single drug to combination". Starting from the epigenetics of tumors, Dr. Lu described that mutations or abnormal chemical modifications of epigenetic factors can affect transcription, metabolism, immunity, DNA repair, cell cycle, etc.. Epigenetics regulation is closely related to many links of tumor occurrence and development. This paper introduces the Chidamide, the benzamide histone deacetylase inhibitor (HDACi ), which is different from the previous epigenetic drugs and has a novel anti-tumor immune regulation mechanism. The formulation and implementation of the comprehensive treatment plan in the future to maximize the benefits of more cancer patients will be the main research direction of Chidamide as the original epigenetic regulator.

Chidamide is currently the only histone deacetylase inhibitor (HDACi) independently developed and listed in China. China's Food and Drug Administration (CFDA) has approved its use in the treatment of peripheral T-cell lymphoma (PTCL) and successfully incorporated it into the national health care catalog in July this year, which undoubtedly shows Chidamide's important therapeutic position. The HDACi summit this year has a total of 13 top domestic experts who have made in-depth discussions on HDACi from basic to clinical aspects. At present, CHIPSCREEN BIOSCIENCES is working with Chinese clinical tumor experts to continuously expand the clinical application space of new drugs by the results of scientific research based on the mechanism of action of new drugs in combination with unmet clinical needs. We expect these results to lead the research direction in the HDACi field and better benefit Chinese patients while making domestic new drugs and their research results go to the world.